Document is current
Any future updates will be listed below
-
Authors
Aasa, Maja
Lindquist, David
Ottander, Ulrika
Strandberg, Sara N. https://orcid.org/0000-0002-0943-8178
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05855941 at ClinicalTrials.govDocuments that mention this clinical trial
Primary staging with 2[18F]-FDG-PET/CT and -PET/MRI and radiotherapy response evaluation with MRI in uterine cervical cancer: an interim analysis of a prospective clinical trial
https://doi.org/10.1186/s41824-024-00236-2
-
Funding
Funding for this research was provided by:
Medicinska fakulteten, Umeå Universitet
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 20 December 2024
First Online: 10 January 2025
Declarations
:
: The PRODIGYN study (Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer) was approved by the Swedish Ethical Review Authority with ethical approval number 2022-04207-01; NCT05855941. Study participants were given oral and written information and had the opportunity to ask questions. Written informed consent was obtained from all study participants.
: Written informed consent was obtained from all study participants.
: The authors declare no competing interests.
